Background Coronary stenting is associated with two major complications: subacute thrombosis and neointimal proliferation resulting in restenosis. Our hypothesis is that the biocompatibility of metallic stents can be improved by coating with a polymer membrane that delivers agents that favorably modify the local arterial microenvironment. This study evaluates the kinetics, distribution, and bioactivity of the model drug forskolin delivered to the local arterial wall by a polyurethanecoated removable metallic stent.
Background Coronary stenting is associated with two major complications: subacute thrombosis and neointimal proliferation resulting in restenosis. Our hypothesis is that the biocompatibility of metallic stents can be improved by coating with a polymer membrane that delivers agents that favorably modify the local arterial microenvironment. This study evaluates the kinetics, distribution, and bioactivity of the model drug forskolin delivered to the local arterial wall by a polyurethanecoated removable metallic stent.
Methods and Results Stents were used in rabbit carotid arteries (n=20) for as long as 24 hours. The quantity of forskolin bound to the stent decreased exponentially with a half-life of 5.8 hours. Blood concentrations peaked at 140±39 pg/pL at 4 hours. The adjacent arterial media contained 60±39 ng/mg, which was 380-and 460-fold greater than the contralateral carotid media and the systemic blood, respectively (P<.0001). Media forskolin concentrations declined exponentially over time with a tissue half-life of 5.0 hours. Drug distributed throughout the vessel wall with decreasing gradients in the radial and axial dimensions consistent with a diffusion process. Removal of the stent was associated with a 100-fold decline in media forskolin concentration within 2 hours. Forskolin release was associated with a sustained 92% increase in carotid blood flow and a 60% decrease in local arterial resistance compared with coated control stents (P<.005). In another set of rabbits (n=14) using a carotid crush injury, flow-reduction model, forskolin prolonged the time to flow variation and occlusion by 12-fold compared with the use of bare metal stents and 5-fold compared with the use of polyurethane-coated stents (P<.0001).
Conclusions A polymer-coated metallic stent can deliver forskolin to the local arterial wall in high concentrations relative to the blood or other tissues. High local drug concentrations are dependent on maintaining stent-to-tissue gradients. The O ur fundamental aim is to improve the biocompatibility of metallic coronary stents by developing a polymer membrane coating that can deliver pharmacological agents locally in high concentrations. Coronary stenting is associated with two major complications: subacute thrombosis and restenosis resulting from vascular smooth muscle cell proliferation.1-5 A successful method of preventing these complications in humans has not been found. The precise mechanisms through which metallic stents stimulate thrombus formation and neointimal hyperplasia are not fully understood. One reason that systemically administered pharmaceutical agents fail to prevent these complications may be that the tolerated dose is too low to achieve sufficient drug concentration at the targeted site. A stent capable of delivering effective agents precisely to the site of arterial injury for a sufficient time period may be advantageous for discovering and implementing successful treatment strategies.
The purpose of this study was to test the feasibility of local drug delivery from a polyurethane-coated metallic stent. We used a new type of stent called the heatactivated removable temporary stent (HARTS). This device functions like other permanent coronary stents but has the option of reliable percutaneous removal for at least 1 week after deployment.6 Removability allows assessment of persistence of delivered substances in tissue irrespective of the presence of the delivery system or maintenance of blood levels. We chose forskolin, a nonpolar adenylate cyclase activator with antiplatelet and vasodilator properties, as a model drug.7-9 Using a rabbit carotid artery model of temporary stent implantation, our goals were to quantify the kinetics of forskolin release, distribution, and persistence in blood, local arterial wall, and distant tissues and to determine if the drug delivered by the stent is biologically active.
Methods
Drug Delivery System A prototype HARTS (Advanced Coronary Technologies) was selected as the drug delivery device for this study (Fig 1A) . The technical details of this stent have been previously reported. 6 The stent is constructed from 0.009-in-diameter wire segments of the shape-memory nickel-titanium alloy nitinol. The stent is percutaneously implanted into the vessel wall by balloon expansion and subsequently recovered to its predeployment dimensions by transiently heating it to the selected thermoelastic transition temperature of 55°C. This property permits percutaneous extraction, which has been accomplished as long as 1 week after deployment in canine coronary arteries. In experiments where the stent was recovered, a 3F catheter with multiple distal sideholes was passed over a guide wire until it was coaxial within the stent. Five milliliters of normal saline heated to 65°C was rapidly injected, resulting in immediate collapse of the stent to its predeployment diameter, tightly gripping the catheter. The stent and catheter were then withdrawn percutaneously. Previous experiments (unpublished data) in canine and porcine coronary arteries have shown no histological evidence of short-or long-term thermal injury with this recovery procedure.
To quantify tissue uptake, we implanted drug-impregnated stents, and euthanasia with rabbits under anesthesia was performed with stents remaining in situ after 2 hours in two rabbits, 4 hours in six rabbits, and 24 hours in three rabbits (group la, n=11). To quantify tissue persistence of drug, stents were percutaneously removed after 2 hours (group lb, n=4). Two of the rabbits were euthanized while under anesthesia at 4 hours and two at 24 hours (ie, 2 and 22 hours after stent removal). To assess whether hemodynamic changes were mediated by local forskolin action, additional rabbits underwent implantation with stents containing no drug but coated with the polymer membrane (group 1 control, n=5). Otherwise, the protocol was identical to group la with euthanasia at 4 hours.
In a single experiment to evaluate the uniformity of tissue uptake of a lipophilic drug, a coated stent was similarly impregnated with rhodamine B (2.5 mg) and used in one rabbit carotid artery for 4 hours. Frozen sections (10 ,um) of the stented arterial segment and the contralateral artery were examined with light and fluorescent microscopy.
Another series of rabbit experiments (group 2) was performed to evaluate the antithrombotic activity of locally delivered forskolin using a carotid artery crush injury, reduced-flow model modified for stent implantation.17 New Zealand White rabbits (n=14) underwent the same anesthesia, surgical, and blood flow-monitoring protocol described for group 1 with the following differences. Systemic anticoagulants were withheld. Crush injury was performed with a plastic-coated clamp at a similar force for 15 repetitions over a 1-cm length of the mid right common carotid artery. After 5 minutes, stents (five bare metal, four polyurethane-coated, and five forskolin-loaded) were advanced to straddle the area of injury, and the balloon was expanded to a diameter of 3.0 mm. A perivascular constriction balloon was placed 1 cm proximal to the stent, followed by a 15-minute equilibration period. The occluder was inflated to reduce flow to 4 mL/min (averaging 49% of baseline flow). To ensure maintenance of consistent stenosis, a pressure transducer was placed in-line with the flow-constricting balloon. If the flow remained <0.5 mL/min for 5 minutes, the artery was considered occluded. If the artery exhibited flow <0.5 mL/min but returned to flow >0.5 mL/min, intermittent occlusion or flow variation was determined to be present. Experiments were terminated at the time of artery occlusion, or at 4 hours. The time from flow restriction until flow variation and experiment termination was recorded. After euthanasia with the rabbits under anesthesia, the artery was explanted and cut longitudinally with a scalpel, and the stent was removed. The polyurethane coating was inspected for defects under a dissecting microscope at x 10, and the presence of white or red thrombus was recorded. The amount of thrombus present was qualitatively assessed as occlusive if no lumen remained through the stent, nonocclusive if thrombus partially occupied the lumen, and minor if present on the stent or artery wall without encroachment of the lumen.
Forskolin Distribution and Kinetics
In group 1 experiments, samples of adventitia were removed, and the carotid artery was sectioned into 1-cm segments from the stented region and the segments proximal and distal to the stent. Additional samples were obtained from the stermocleidomastoid muscle, uninvolved contralateral carotid artery, liver, and kidney. Tissue samples were weighed (10±6 mg for carotid artery media/intima, 12±7 mg for adventitia, and 23±12 mg for other tissues) immediately after collection and digested in 1.0 mL of BTS-450 (Beckman) at 40°C for 24 hours and counted for 1 minute in 10 mL of Ready Organic scintillation fluid (Beckman). Blood samples (0.5 mL) were digested in 1.5 mL of 1: 2 BTS450/isopropanol at 40°C for 24 hours, decolorized with H202, and counted in 18 mL of Safety Sol scintillation fluid (RPI). Scintillation fluid contained 0.7% acetic acid to reduce chemoluminescence. Scintillation counts were then adjusted for measured background and efficiency. The amount of forskolin present was calculated by comparison of tissue activity with a 25-,uCi/mg standard. For comparison of tissue and blood forskolin concentrations, blood levels were divided by specific gravity of rabbit blood (1.050 g/mL). The forskolin content of stents before use and after explantation was measured by scintillation counting of aliquots of the stent coating dissolved in tetrahydrafuran.
Instantaneous net rate or flux of forskolin accumulation in the carotid arterial blood was calculated using the conservation of mass principle with the fickian assumptions of instantaneous mixing and insignificant spatial distribution affects. 18 (1)
where M is the amount of forskolin, Q is carotid blood flow, and C is the concentration of blood forskolin in the carotid distal to the stent and in the systemic arterial blood.
First-order kinetic modeling was performed by a leastsquares fit of a monoexponential function of the general form (2) Y=a0exp (-a,t) where Y is the measured variable that can be the drug mass, tissue concentration, or blood flux; ao is the amplitude at time zero; and the decay half-life is a1/0.693.
The forskolin content of the stent coating was also compared with previous observations of diffusion from 6 .9±1.9 ,ug/min, declined monotonically and was closely described by a single exponential decay function with a half-life of 1.2 hours. The total mass of forskolin entering the carotid blood in the first 4 hours was 649 ,g, or 61% of the forskolin released from the stent. Fig 5 shows the distribution of tissue forskolin concentration at 4 hours after implantation. The carotid media of the stented segment contained 60±39 ng/mg, which averaged 380-fold higher than similar tissue from the contralateral carotid artery and 460-fold higher than the concentration of forskolin in the systemic arterial blood. Media and adventitia overlying the stent and sections proximal and distal to the stent all had significantly higher concentrations of forskolin compared with blood, contralateral artery, liver, and kidney (P<.0001).
Fig 6 shows the distribution of rhodamine B in the ipsilateral and contralateral arteries 4 hours after stenting. Fluorescent microscopy showed intense uptake of rhodamine throughout the media and adventitia of the stented artery. Light microscopy revealed that the in- tensity of staining varied circumferentially and radially with respect to the lumen. The most intense staining was at the sites of stent contact along the inner circumference. Staining diminished in between these sites and with distance radially outward from the lumen surface but extended throughout the media and adventitia. The contralateral unstented artery contained no rhodamine by either method of microscopic examination. Fig 7 shows the time course of forskolin concentration in the media of the ipsilateral carotid artery: in group la, with the stent present as a drug reservoir, and in group lb, where the stent was removed at 2 hours. With the stent continuously present, tissue forskolin decreased from 134±2 ng/mg at 2 hours to 4.9± 1.2 ng/mg at 24 hours but remained 77-fold greater than the simultaneous blood concentration. Arterial media concentrations followed a time course similar to drug bound to the stent with a half-life of 5.0 hours. After stent removal, media washout was brisk, decreasing to 1.2±0.2 ng/mg after 2 hours and further declining to 0.2±0.1 ng/mg after 22 hours. Biological Activity Fig 8 shows the effect of implanting forskolin-loaded stents on carotid blood flow, mean aortic blood pressure, and local carotid resistance in group la rabbits with forskolin-loaded stents compared with group 1 control coated stents. Carotid blood flow increased immediately after implantation of forskolin-containing stents and remained elevated by an average of 92±46% for the duration of the experiment. This change was significant compared with controls, in which blood flow declined by 21+26% (P<.005). Mean aortic blood pressure decreased modestly after forskolin-loaded stent implantation compared with controls, but this difference was not significant (-27±20% versus -6+15%, respectively; P=.11). Local carotid resistance fell significantly after implantation of forskolin-loaded stent compared with controls (-60±10% versus 44±59%, respectively; P<.005).
The Table summarizes the results of the crush injury, flow-reduction model in group 2 animals. Implantation of forskolin-loaded stents was associated with a significant increase in the time to flow variation and the time to occlusion compared with the use of bare metal (>12-fold) and polyurethane-coated (>5-fold) stents. There also was a mild but significant increase in time to occlusion for the non-drug-containing coated stents compared with the bare metal stents. On inspection, all bare metal stents had occlusive mixed red and white thrombi; all polyurethane stents were obstructed by predominantly white thrombi. Only one of five forskolin-loaded stents had a nonocclusive thrombus, which was red. The four other forskolin stents had minor amounts of thrombi (Fig 1B) .
Discussion
The present study demonstrates the potential of a polymer-coated metallic stent for short-term local arterial wall delivery of biologically active lipophilic agents. Four hours after implantation, the arterial media of the stented rabbit carotid segment had 460-fold higher concentrations of forskolin compared with blood and 380-fold higher concentrations than the control contralateral artery. implantation, more than 95% of the original forskolin mass was no longer detected in the stent coating. This exponential temporal dependency suggests that forskolin release is largely proportional to the mass of drug remaining in the polymer matrix and can be modeled as a first-order or diffusion-limited system. Moreover, the data are consistent with an empirically derived model of diffusion from membranes with slab geometry. Forskolin transit into the carotid blood was immediate (Fig 3) with a peak concentration gradient between the distal carotid blood and the systemic circulation developing within 1 minute. This gradient progressively narrowed and was nearly abolished after 4 hours. The net flux of forskolin entry into the carotid blood was also very closely predicted (r=.997) by a monoexponential decay function with a half-life of 1.2 hours. The shorter half-life is most likely indicative of drug distributing from the blood into tissue compartments such that by 4 hours, the net amount of forskolin entering the blood was 61% of the drug eluted off the stent.
One potential problem with this type of local drug delivery device was that mechanical deformation of the polyurethane or loosely bound drug on the surface of the coating could create a substantial bolus effect on deployment, resulting in untoward systemic effects. with forskolin-into the femoral circulation of sheep. Five minutes after placement, there was a fourfold overshoot compared with steady-state levels, which were achieved only 10 minutes later. By 30 minutes, more than 90% of the drug had eluted off the grafts. In the present study, inspection of explanted stents by dissecting microscope revealed that the polyurethane coating was intact without rupture or sloughing. The observation that systemic arterial levels increased immediately, reaching 57+26 pg/,uL within 1 minute after deployment, which was 41% of the steady-state concentration at 4 hours, may represent a small bolus effect. The robustness of the fit of the exponential model to the blood flux data, especially of the 1-minute samples (Fig  4) , strongly suggests that the bolus effect related to stent deployment was minor. In addition, the absence of early hypotension or transient changes in flow or resistance argues against a sizable bolus effect.
Tissue Distribution
The most important observation of our study was the demonstration of high local arterial wall concentrations of drug compared with systemic blood or other organs. There was a decreasing concentration gradient of forskolin with distance from the stent in both radial and axial dimensions. The time dependency of arterial media forskolin levels closely paralleled the amount of drug remaining on the stent with half-lives of 5.0 and 5.8 hours, respectively. The frozen sections of vessel implanted with a stent containing the lipophilic fluorescent dye rhodamine B showed that drug deposition is relatively higher near the location of the struts and confirmed that there was uptake of drug throughout the media and adventitia. These data suggest that this class of small lipophilic molecules diffuse directly from the stent, although distribution involving the vasovasorum cannot be excluded. Removal of the stent was associated with a >100-fold decline in adjacent tissue levels within 2 hours. Tissue washout over the next 20 hours was slower with a half-life of about 8 hours. These observations indicate that high local drug concentrations are dependent on maintaining stent-to-tissue gradients.
Although delivery of pharmaceuticals directly to the arterial wall has been reported using perforated balloons and balloon occlusion systems, few studies have quantified tissue drug levels. Van precisely to the site of arterial injury where the stent has been embedded into the arterial wall. The HARTS stent or similar devices may confer an additional advantage in that they can be removed once therapeutic goals are achieved or if there are untoward effects. The choice of a removable or permanent stent for local drug delivery will depend on to-be-determined factors such as the cost versus benefit of each procedure.
Drug Effects
The bioactivity of forskolin delivered by the stent was demonstrated in two phases of this study. In controlled experiments, implantation of forskolin-containing stents was associated with an immediate, sustained, and significant 92% increase in carotid blood flow and a 60% decrease in carotid resistance, consistent with the known vasodilatory effects of forskolin.17 The observation that mean systemic blood pressure decreased slightly suggests that local changes in resistance accounted for the increase in carotid blood flow. Second, in the crush injury-thrombosis model (group 2), forskolin-loaded stents were associated with a 12-fold prolongation in the time to cyclic flow variations and total occlusion compared with the uncoated stent, whereas polyurethane coating alone mildly prolonged the time to stent thrombosis. The absence of occlusive platelet-rich white thrombus in the forskolin-treated rabbits is consistent with the antiplatelet aggregation properties of forskolin. 19 
Study Limitations
This study has several important limitations. The simple linear kinetic model for forskolin release, blood flux, and tissue retention should be considered a rough approximation. Although it suggests a first-order or diffusion-limited mechanism, it may be applicable only within a narrow range of drug concentrations tested. Forskolin uptake is likely a much more complex kinetic process involving multiple, spatially distributed compartments and transport and receptor mechanisms. Mechanical factors, including the degree of stent strut contact with the vessel wall and the geometry of the polymer membrane, may also be important considerations.
We did not evaluate the biocompatibility of the polyurethane coating or the potential for the high local concentration of drug to be cytotoxic to the arterial wall. Preliminary studies suggest that a commonly used biostable polymer, polyurethane-urea, induces a marked chronic inflammatory response when used as a coating on permanently implanted stents.2324 There are no reports of inflammatory responses to the type of polyurethane coating used in our study. Tecoflex may be more biocompatibles because it lacks reactive aromatic side chains, but this requires further evaluation. Polyurethane membranes can be made more hemocompatible by surface treatments with crosslinked albumin, poly(ethylene-oxide), or heparin. 25 The effect of forskolin on intimal hyperplasia was not evaluated. The distribution of forskolin into atherosclerotic plaque is unknown. Despite the dramatic prolongation of the time to stent thrombosis in the crushinjury, low-flow model, no inference can be made about inhibition of subacute thrombosis, an event that occurs several days after implantation in humans. Prevention of subacute thrombosis or the proliferative component of restenosis may require maintenance of high tissue levels for days to weeks. With the current method of drug incorporation, the stent coating as a forskolin reservoir was 95% exhausted by 24 hours, and the adjacent medial concentration had decreased to 4.9 ng/mg. Even so, this level is still 12-fold greater than the effective concentration or EC50 of forskolin, which has been reported to be approximately lx10`6 mol/L for canine and porcine coronary vasodilation.1"26 Moreover, vascular grafts impregnated with forskolin inhibit platelet accumulation for up to 4 days and graft patency at 3 months is significantly improved, despite the fact that graft forskolin content is 90% depleted within 30 minutes.19,2' These data suggest that there may be sufficient forskolin present on the stent to exert an effect for several days, but this too requires specific testing. Drugs with high binding affinities for the stent coating or tissues or with poorer water solubility may persist in the arterial wall for longer periods. Covalent crosslinking of the polymer membrane surface may further retard the rate of drug release. As such, the pharmacokinetics and duration of bioactivity of different drugs delivered by a polyurethane coated stent are likely to vary substantially and need to be documented for each combination of therapeutic agent and coating.
A further limitation is that polyurethane does not absorb water-soluble drugs. This limitation might be overcome by modification of the polymer matrix with aqueous channels or surfactant molecules that ionically bind polar molecules. Water-soluble molecules can be made more nonpolar by the addition of lipid side chains. These modifications may broaden the number of therapeutic compounds that can be delivered by this system.
In conclusion, this report demonstrates that a polymer-coated metallic stent can deliver forskolin to the local arterial wall in high concentrations relative to the blood or other tissues. Delivery of forskolin can be modeled as a simple diffusion process. High local concentrations are dependent on maintaining stent-to-tissue gradients. The delivered drug is biologically active, demonstrating vasodilating and antiplatelet properties. These data suggest the feasibility of a hybrid stent/local drug delivery system to improve the biocompatibility of metallic stents by modification of the microenvironment. Further research is required to determine the pharmocokinetic and biological effects of various candidate drugs delivered by this system and whether stent removal hours to days after implantation confers any clinical advantages.
